WASHINGTON, (EP/AP) A study conducted by researchers from the Harvard Medical School, in the united States, ensures that the compa&bath;’s insurance can’to compensate econ’dynamically "long term" pay the price of certain medicines to the insured persons who have suffered heart attacks.
A combination’n medicines for the heart’n fármacos to lower cholesterol levels can reduce the risk of death by disease cardíaca in patients with an 80% chance from placebo. However, these medications do not tend to be used by the largestía of these patients. A solution’re the problem, couldíto be that these compa&bath;’s pay fármacos del coraz’n to those insured patients who previously suffered a heart attack. Taking into account the possibility raised by this research’n, if the insurer is in charge of spending on fármacos, medication’re among this type of patients couldíto increase by 50 to 63%. The extra coverage couldíto reach cost these compa&bath;’s an average of 550 d’dollars per patient but it couldíto reduce the deaths by heart attack or apoplej’to, saving companies 1.731 d’lares spent at sick of the heart’re. "If insurance companies can increase rates of medication’n, and to prevent, así illness card’acas even haciéhaving to bear these costs, the initiative habrá worth it", explained’ Niteesh K. Choundry, a professor holder of Harvard. The researchers&bath;alaron in his report that a few 423.000 americans who have insurance médico to pay the price of their medicines had their first attack at the heart’n in 2006. Scholars americans calculated that to cover all the expenses in fármacos for the heart’n the insured can’to save an average of 4.736 lives each a&bath;or, and save’an, of the compa&bath;’s insurance más 2,500 million d’lares annual, about 1.920 million euros